 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE:ADCT, a commercial-stage biotechnology company leading the development of novel antibody drug conjugates ADCs to treat hematological malignancies and solid tumors, today announced it had entered into a royalty purchase agreement with HealthCare Royalty Partners HealthCare Royalty. Under the terms of the 325 million financing agreement, ADC Therapeutics will receive 225 million upon closing, and is eligible to receive an ad 